Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 2/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421894 | 0.95 | ALDH1A1 (0.50) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL2970113 | 0.88 | ALDH1A1 (0.56) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL3691375 | 0.88 | KMT2A (0.51) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL3696029 | 0.88 | KMT2A (0.51) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL2970252 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL6225860 | 0.86 | ALDH1A1 (0.55) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL3983582 | 0.83 | ALDH1A1 (0.49) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL3421733 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL3420532 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAKMT2ANPSR1MEN1 | |
| SCHEMBL3692474 | 0.82 | KMT2A (0.55) | ALDH1A1LMNAKMT2ANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776924-B2 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-08-17 | — | — | US | disclosed |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-01-14 | — | — | US | disclosed |
| US-7629332-B2 | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-12-08 | — | — | US | disclosed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | disclosed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | disclosed |
| US-5750782-A | ANTICARCINOGENIC AGENTS, ANTIHYPOXIC AGENTS, PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| EP-0616609-B1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CANCER RES CAMPAIGN TECH (GB) | 1997-06-18 | — | — | EP | disclosed |
| US-5571845-A | Nitroaniline derivatives and their use as anti-tumour agents | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-11-05 | — | — | US | disclosed |
| EP-0616609-A1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS. | CANCER RES CAMPAIGN TECH (GB) | 1994-09-28 | — | — | EP | disclosed |
| WO-1993011099-A1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, PNP | ALDH1A1 184/4885LMNA 3817/4885KMT2A 1372/4885 |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, QDPR | ALDH1A1 164/4885LMNA 3848/4885KMT2A 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.